Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CRYSELLE vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cryselle is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin release, primarily through estrogenic and progestogenic effects on the hypothalamic-pituitary axis. It also increases cervical mucus viscosity and alters endometrial structure, impeding sperm penetration and implantation.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Off-label: Acne vulgaris, dysmenorrhea, menorrhagia, endometriosis-associated pain, menstrual cycle regulation, emergency contraception (sometimes off-label)
Prevention of pregnancy (FDA-approved)
One tablet (0.3 mg norgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life approximately 24 hours (range 16-36 h), with clinical significance for once-daily dosing.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol undergoes first-pass metabolism in the gut wall and liver, primarily via CYP3A4, and is also involved in conjugation (glucuronidation and sulfation). Norgestrel is metabolized in the liver via reduction and conjugation, with the active isomer levonorgestrel undergoing hydroxylation by CYP3A4.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal (50% as metabolites, 20% unchanged), fecal (30%), with enterohepatic recirculation.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
95-98% bound to serum albumin and sex hormone-binding globulin.
~99% bound to serum albumin and sex hormone-binding globulin.
Approximately 2 L/kg (40-60 L total), indicating extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 85-90% due to first-pass metabolism; otherwise 100% for IV.
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in patients with acute or chronic renal failure due to potential for fluid retention and electrolyte disturbances.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in patients with Child-Pugh Class B or C cirrhosis or active liver disease. Use with caution in Child-Pugh Class A; consider alternative therapy if hepatotoxicity risk outweighs benefits.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for premenarchal girls. Postmenarchal adolescents: same dosing as adults (0.3 mg norgestrel/0.03 mg ethinyl estradiol once daily for 21 days, then 7 days placebo).
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use in postmenopausal women. No specific dosing adjustments recommended for elderly patients, but use with caution due to increased risk of thromboembolic events and cardiovascular disease.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Cardiovascular events (thrombophlebitis, venous thrombosis, arterial thromboembolism, myocardial infarction, stroke, pulmonary embolism),Hepatic neoplasia (benign and malignant),Gallbladder disease,Carbohydrate and lipid metabolism effects,Elevated blood pressure,Ocular lesions (retinal thrombosis),Headache (including migraine with focal symptoms),Irregular bleeding,Depression,Lactation (may decrease milk production),Hereditary angioedema exacerbation,Chloasma
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component,Heavy smoking (≥15 cigarettes/day) and age >35 years
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions; however, grapefruit juice may increase estrogen levels slightly but clinical significance is minimal. St. John's Wort reduces contraceptive efficacy. High-fat meals can increase absorption of estrogen.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
CRYSELLE (levonorgestrel/ethinyl estradiol) is contraindicated in pregnancy. First trimester: no increased risk of major birth defects from inadvertent use, but postmarketing data limited. Second and third trimesters: associated with increased risk of fetal harm including cardiovascular and genital anomalies, and potential feminization of male fetuses due to progestin exposure.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Excreted in breast milk; M/P ratio approximately 0.1-0.5 for levonorgestrel and 0.02-0.1 for ethinyl estradiol. Combined hormonal contraceptives may reduce milk production and quality; use alternative contraception during breastfeeding. Not recommended while nursing.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dosing adjustments applicable as use is contraindicated during pregnancy. Pharmacokinetic changes of pregnancy (increased volume of distribution, altered metabolism) would require dose increase if used, but due to fetal risk, do not administer.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Crysell is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It is also used off-label for dysmenorrhea and endometriosis-associated pain. Monitor for hypertension, thromboembolic events, and hepatic adenoma. Smoking increases thromboembolism risk, especially in women over 35. Breakthrough bleeding common in first 3 cycles; if persistent, rule out pregnancy or missed pills. Altered efficacy with hepatic enzyme inducers (e.g., rifampin, carbamazepine).
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time; do not skip doses.,Missed pills increase pregnancy risk; follow instructions in package insert.,Antibiotics (except rifampin) do not decrease effectiveness, but rifampin requires backup contraception.,Smoking while on this pill increases risk of blood clots, especially if over 35.,Report severe headaches, vision changes, chest pain, leg swelling or pain, or shortness of breath.,This does not protect against HIV or other STIs.,Breakthrough bleeding is common in first few months; contact provider if heavy or persistent.,If vomiting or diarrhea within 4 hours of a pill, take another pill and use backup contraception.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CRYSELLE vs AFIRMELLE, answered by our medical review team.
CRYSELLE is a Oral Contraceptive that works by Cryselle is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin release, primarily through estrogenic and progestogenic effects on the hypothalamic-pituitary axis. It also increases cervical mucus viscosity and alters endometrial structure, impeding sperm penetration and implantation.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CRYSELLE and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CRYSELLE is: One tablet (0.3 mg norgestrel/0.03 mg ethinyl estradiol) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CRYSELLE and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CRYSELLE is classified as Category C. CRYSELLE (levonorgestrel/ethinyl estradiol) is contraindicated in pregnancy. First trimester: no increased risk of major birth defects from inadvertent use, but postmarketing data . AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.